{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-045995","form_type":"8-K","ticker":"ADCT","cik":"0001771910","company_name":"ADC Therapeutics SA","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.556427+00:00","generated_at":"2026-05-30T03:42:24.204922+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ADC Therapeutics reports Q3 2024 revenue $18.0M; net loss narrows; discontinues ADCT-601","bullets":["ZYNLONTA net product revenue $18.0M in Q3 2024 vs $14.3M in Q3 2023; year-to-date $52.9M.","Net loss $44.0M ($0.42 per share) in Q3 2024 vs $46.7M ($0.57) in Q3 2023; adjusted net loss $29.4M.","Cash and cash equivalents $274.3M as of Sep 30, 2024; expected runway into mid-2026.","Discontinued ADCT-601 (AXL-targeting) due to unfavorable benefit-risk; prioritizing exatecan-based ADC platform.","LOTIS-5 Phase 3 trial (ZYNLONTA+rituximab) full enrollment expected by year-end 2024; LOTIS-7 data update in Dec 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-045995","json":"https://secwatch.observer/filing/0001628280-24-045995.json","markdown":"https://secwatch.observer/filing/0001628280-24-045995.md","text":"https://secwatch.observer/filing/0001628280-24-045995.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771910/000162828024045995/0001628280-24-045995-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771910/000162828024045995/adc-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:42:24.204922+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}